| Identification | Back Directory | [Name]
EMPA | [CAS]
680590-49-2 | [Synonyms]
EMPA, CID 9981404
N-ETHYL-2-[(6-METHOXYPYRIDIN-3-YL)-(2-METHYLPHENYL)SULFONYLAMINO]-N-(PYRIDIN-3-YLMETHYL)ACETAMIDE
N-Ethyl-2-[(6-methoxy-3-pyridinyl)[(2-methylphenyl)sulfonyl]amino]-N-(3-pyridinylmethyl)-acetamide
Acetamide, N-ethyl-2-[(6-methoxy-3-pyridinyl)[(2-methylphenyl)sulfonyl]amino]-N-(3-pyridinylmethyl)- | [Molecular Formula]
C23H26N4O4S | [MOL File]
680590-49-2.mol | [Molecular Weight]
454.54 |
| Chemical Properties | Back Directory | [Boiling point ]
660.7±65.0 °C(Predicted) | [density ]
1.280±0.06 g/cm3(Predicted) | [storage temp. ]
-20°C | [solubility ]
Soluble to 100 mM in DMSO and to 100 mM in ethanol | [form ]
Powder | [pka]
4.77±0.10(Predicted) | [color ]
white to light brown | [InChI]
1S/C23H26N4O4S/c1-4-26(16-19-9-7-13-24-14-19)23(28)17-27(20-11-12-22(31-3)25-15-20)32(29,30)21-10-6-5-8-18(21)2/h5-15H,4,16-17H2,1-3H3 | [InChIKey]
KJPHTXTWFHVJIG-UHFFFAOYSA-N | [SMILES]
[S](=O)(=O)(N(CC(=O)N(CC)Cc3cnccc3)c2cnc(cc2)OC)c1c(cccc1)C |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
22 | [WGK Germany ]
3 | [Storage Class]
11 - Combustible Solids | [Hazard Classifications]
Acute Tox. 4 Oral |
| Hazard Information | Back Directory | [Description]
EMPA is an orexin 2 receptor (OX2R) antagonist (Ki = 1.1 nM). It is selective for OX2R over OX1R (Ki = 900 nM). EMPA inhibits orexin-A- and orexin-B-induced calcium mobilization (IC50s = 8.8 and 7.9 nM, respectively) and increases orexin-A- and orexin-B-induced inositol phosphate accumulation (EC50s = 1.1 and 2.4 nM, respectively) in CHO(dHFr-) cells expressing recombinant human OX2R. It reduces spontaneous locomotor activity and orexin-B-induced hyperlocomotion in mice when administered at doses ranging between 10 and 300 mg/kg. | [Uses]
EMPA is a novel high-affinity, selective antagonist for the OX2 receptor. | [in vivo]
EMPA (1-300 mg/kg; i.p.) dose-dependently reverses this [Ala11,D-Leu15]orexin-B-induced hyperlocomotion without itself significantly affecting locomotor activity (LMA) in male NMRI mice[1].
EMPA (3-30 mg/kg; i.p.) induces a significant and dose-dependent reduction in the baseline LMA in france and male Wistar rats. EMPA (3-30 mg/kg; i.p.) demonstrates a clear dose-dependent inhibition of spontaneous activity as compared with vehicle-treated animals[1]. | Animal Model: | Male NMRI mice (20-30 g)[1] | | Dosage: | 1, 3, 10, 30, 100, 300 mg/kg | | Administration: | Injected i.p. at a volume of 10 mL/kg | | Result: | Dose-dependently reversed this [Ala11,D-Leu15]orexin-B-induced hyperlocomotion without itself significantly affecting LMA. |
| Animal Model: | France and Male Wistar rats (196-237 g)[1] | | Dosage: | 3, 10, 30 mg/kg | | Administration: | Injected i.p. at a volume of 5 mL/kg | | Result: | Induced a significant and dose-dependent reduction in the baseline LMA.
Demonstrated a clear dose-dependent inhibition of spontaneous activity as compared with vehicle-treated animals. |
| [IC 50]
OX2 Receptor | [storage]
Store at -20°C | [References]
[1] P MALHERBE. Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX2 receptor[J]. British Journal of Pharmacology, 2009, 156 8: 1326-1341. DOI: 10.1111/j.1476-5381.2009.00127.x |
|
|